H. R. 1919

IN THE SENATE OF THE UNITED STATES

JUNE 4, 2013

Received; read twice and referred to the Committee on Health, Education, Labor, and Pensions

AN ACT

To amend the Federal Food, Drug, and Cosmetic Act with respect to the pharmaceutical distribution supply chain, and for other purposes.

1 Be it enacted by the Senate and House of Representa-
2 tives of the United States of America in Congress assembled,
SECTION 1. SHORT TITLE.

(a) SHORT TITLE.—This Act may be cited as the “Safeguarding America’s Pharmaceuticals Act of 2013”.

(b) TABLE OF CONTENTS.—The table of contents of this Act is as follows:

Sec. 1. Short title.
Sec. 2. Pharmaceutical distribution supply chain.
Sec. 3. Enhanced drug distribution security.
Sec. 4. National standards for wholesale distributors.
Sec. 5. National licensure standards for third-party logistics providers.
Sec. 6. Penalties.
Sec. 7. Uniform national policy.
Sec. 8 Electronic labeling.

SEC. 2. PHARMACEUTICAL DISTRIBUTION SUPPLY CHAIN.

Chapter V of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 351 et seq.) is amended by adding at the end the following:

“Subchapter H—Pharmaceutical Distribution Supply Chain

“SEC. 581. DEFINITIONS.

“In this subchapter:

“(1) AUTHORIZED.—The term ‘authorized’ means—

“(A) in the case of a manufacturer or re-packer, having a valid registration in accordance with section 510; and

“(B) in the case of a wholesale distributor, third-party logistics provider, or dispenser, licensed (as defined in this section).

“(2) DISPENSER.—The term ‘dispenser’—
“(A) subject to subparagraph (C), means a retail pharmacy, hospital pharmacy, a group of chain pharmacies under common ownership and control, or any other person authorized by law to dispense or administer prescription drugs, to the extent such pharmacy, group, or person does not act as a wholesale distributor;

“(B) includes warehouses and distribution centers under common ownership or control of entities described in subparagraph (A) that are members of an affiliated group pursuant to section 1504(a) of the Internal Revenue Code of 1986, to the extent such warehouses and distribution centers do not act as a wholesale distributor; and

“(C) does not include a person who only dispenses prescription drug product to be used in animals in accordance with section 512(a)(5).

“(3) DISPOSITION.—The term ‘disposition’, with respect to a prescription drug product within the possession and control of an entity—

“(A) means the removal of such prescription drug product, or taking measures to prevent the introduction of such prescription drug
product, from the pharmaceutical distribution supply chain; and

“(B) may include disposal, return of the prescription drug product for disposal, or other appropriate handling and other actions such as retaining a sample of the prescription drug product for additional physical examination or laboratory analysis by a manufacturer or regulatory or law enforcement agency.

“(4) Distribute or distribution.—The terms ‘distribute’ and ‘distribution’ mean the sale, purchase, trade, delivery, handling, or storage of a prescription drug product.

“(5) Illegitimate prescription drug product.—The term ‘illegitimate prescription drug product’ means a prescription drug product which a manufacturer has confirmed—

“(A) is counterfeit, diverted, or stolen;

“(B) is intentionally adulterated such that the prescription drug product would result in serious adverse health consequences or death to humans; or

“(C) is otherwise unfit for distribution such that the prescription drug product is rea-
sonably likely to cause serious adverse human health consequences or death.

“(6) LICENSED.—The term ‘licensed’ means—

“(A) in the case of a wholesale distributor, having a valid license to make wholesale distributions consistent with the standards under section 583;

“(B) in the case of a third-party logistics provider, having a valid license to engage in the activities of a third-party logistics provider in accordance with section 584; and

“(C) in the case of a dispenser, having a valid license to dispense prescription drugs under State law.

“(7) MANUFACTURER.—The term ‘manufacturer’ means, with respect to a prescription drug product—

“(A) a person that holds an application approved under section 505 or a license issued under section 351 of the Public Health Service Act for such prescription drug product, or if such prescription drug product is not the subject of an approved application or license, the person who manufactured the prescription drug product;
“(B) a co-licensed partner of the person described in subparagraph (A) that obtains the prescription drug product directly from the person described in such subparagraph; or

“(C) a person that—

“(i) is a member of an affiliated group (as defined in section 1504(a) of the Internal Revenue Code of 1986) to which a person described in subparagraph (A) or (B) is also a member; and

“(ii) receives the prescription drug product directly from a person described in subparagraph (A) or (B).

“(8) PACKAGE.—

“(A) IN GENERAL.—The term ‘package’ means the smallest individual saleable unit of prescription drug product for distribution in interstate commerce by a manufacturer or repackager that is intended by the manufacturer for ultimate sale to the dispenser of such prescription drug product.

“(B) INDIVIDUAL SALEABLE UNIT.—The term ‘individual saleable unit’ means the smallest container of prescription drug product introduced into interstate commerce by the manufac-
turer or repackager that is intended by the manufacturer for individual sale to a dispenser.

“(9) Prescription drug.—The term ‘prescription drug’ means a drug for human use subject to section 503(b)(1).

“(10) Prescription drug product.—The term ‘prescription drug product’ means a prescription drug in a finished dosage form for administration to a patient without substantial further manufacturing (such as capsules, tablets, and lyophilized prescription drug products before reconstitution).

“(11) Prescription drug product identifier.—The term ‘prescription drug product identifier’ means a standardized graphic that—

“(A) includes the standardized numerical identifier, lot number, and expiration date of a prescription drug product; and

“(B) is in both human-readable form and on a machine-readable data carrier that conforms to the standards developed by a widely recognized international standards development organization.

“(12) Quarantine.—The term ‘quarantine’ means to store or identify a product, for the purpose of preventing distribution or transfer of the product,
in a physically separate area clearly identified for
such use, or through use of other procedures such
as automated designation.

“(13) Repackager.—The term ‘repackager’
means a person who owns or operates an establish-
ment that repacks and relabels a prescription drug
product or package for further sale or distribution.

“(14) Return.—The term ‘return’ means pro-
viding prescription drug product to the authorized
trading partner or trading partners from which such
prescription drug product was purchased or received,
or to a returns processor for handling of such pre-
scription drug product.

“(15) Returns processor.—The terms ‘re-
turns processor’ mean a person who owns or oper-
ates an establishment that provides for the disposi-
tion of or otherwise processes saleable and nonsale-
able prescription drug product received from an au-
thorized trading partner such that the prescription
drug product may be processed for credit to the pur-
chaser, manufacturer, seller, or disposed of for no
further distribution.

“(16) Specific patient need.—The term
‘specific patient need’—
“(A) means with respect to the transfer of a prescription drug product from one pharmacy to another, to fill a prescription for an identified patient; and

“(B) does not include the transfer of a prescription drug product from one pharmacy to another for the purpose of increasing or replenishing stock in anticipation of a potential need.

“(17) STANDARDIZED NUMERICAL IDENTIFIER.—The term ‘standardized numerical identifier’ means a set of numbers or characters that—

“(A) is used to uniquely identify each package or homogenous case of the prescription drug product; and

“(B) is composed of the National Drug Code that corresponds to the specific prescription drug product (including the particular package configuration) combined with a unique alphanumeric serial number of up to 20 characters.

“(18) SUSPECT PRESCRIPTION DRUG PRODUCT.—The term ‘suspect prescription drug product’ means a prescription drug product for which there
is reason to believe that such prescription drug prod-
uct—

“(A) is potentially counterfeit, diverted, or
stolen;

“(B) is potentially intentionally adulterated

such that the prescription drug product would
result in serious adverse health consequences or
death to humans; or

“(C) appears otherwise unfit for distribu-
tion such that the prescription drug product
would result in serious adverse health con-
sequences or death to humans.

“(19) THIRD-PARTY LOGISTICS PROVIDER.—
The term ‘third-party logistics provider’ means an
entity that provides or coordinates warehousing, dis-
tribution, or other logistics services of a prescription
drug product in interstate commerce on behalf of a
manufacturer, wholesale distributor, or dispenser of
a prescription drug product, but does not take own-
ership of the prescription drug product, nor have re-
sponsibility to direct the sale or disposition of, the
prescription drug product.

“(20) TRADING PARTNER.—The term ‘trading
partner’ means—
“(A) a manufacturer, repackager, wholesale distributor, or dispenser from whom a manufacturer, repackager, wholesale distributor, or dispenser accepts ownership of a prescription drug product or to whom a manufacturer, repackager, wholesale distributor, or dispenser transfers ownership of a prescription drug product; or

“(B) a third-party logistics provider from whom a manufacturer, repackager, wholesale distributor, or dispenser accepts possession of a prescription drug product or to whom a manufacturer, repackager, wholesale distributor, or dispenser transfers possession of a prescription drug product.

“(21) TRANSACTION.—

“(A) IN GENERAL.—The term ‘transaction’ means the transfer in interstate commerce of prescription drug product between persons in which a change of ownership occurs.

“(B) EXEMPTIONS.—The term ‘transaction’ does not include—

“(i) intracompany distribution of any prescription drug product, including between members of an affiliated group (as
defined in section 1504(a) of the Internal Revenue Code of 1986);

“(ii) the distribution of a prescription drug product among hospitals or other health care entities that are under common control;

“(iii) the distribution of a prescription drug product for emergency medical reasons including a public health emergency declaration pursuant to section 319 of the Public Health Service Act, except that a drug shortage not caused by a public health emergency shall not constitute an emergency medical reason;

“(iv) the dispensing of a prescription drug product pursuant to a valid prescription executed in accordance with section 503(b)(1);

“(v) the distribution of prescription drug product samples by a manufacturer or a licensed wholesale distributor in accordance with section 503(d);

“(vi) the distribution of blood or blood components intended for transfusion;
“(vii) the distribution of minimal quantities of prescription drug product by a licensed retail pharmacy to a licensed practitioner for office use;

“(viii) the distribution of a prescription drug product by a charitable organization to a nonprofit affiliate of the organization to the extent otherwise permitted by law;

“(ix) the distribution of a prescription drug product pursuant to the sale or merger of a pharmacy or pharmacies or a wholesale distributor or wholesale distributors, except that any records required to be maintained for the prescription drug product shall be transferred to the new owner of the pharmacy or pharmacies or wholesale distributor or wholesale distributors;

“(x) the dispensing of a prescription drug product approved under section 512(b);

“(xi) the transfer of prescription drug products to or from any facility that is licensed by the Nuclear Regulatory Commission or by a State pursuant to an agree-
ment with such Commission under section 274 of the Atomic Energy Act of 1954 (42 U.S.C. 2021);

“(xii) the distribution of a combination product that consists of—

“(I) a product comprised of two or more components that are each a drug, biological product, or device and that are physically, chemically, or otherwise combined or mixed and produced as a single entity;

“(II) two or more separate products packaged together in a single package or as a unit and comprised of a drug and device or a device and biological product; or

“(III) two or more finished devices plus one or more drug or biological products which are packaged together in a medical convenience kit described in clause (xiii);

“(xiii) the distribution of a medical convenience kit which is a collection of finished products (consisting of devices or drugs) assembled in kit form strictly for
the convenience of the purchaser or user if—

“(I) the medical convenience kit is assembled in an establishment that is registered with the Food and Drug Administration as a medical device manufacturer;

“(II) the person who manufacturers the medical convenience kit purchased the prescription drug product directly from the manufacturer or from a wholesale distributor that purchased the prescription drug product directly from the manufacturer;

“(III) the person who manufacturers the medical convenience kit does not alter the primary container or label of the prescription drug product as purchased from the manufacturer or wholesale distributor;

“(IV) the medical convenience kit does not contain a controlled substance (as defined in section 102 of the Controlled Substances Act); and
“(V) the prescription drug products contained in the medical convenience kit are—

“(aa) intravenous solutions intended for the replenishment of fluids and electrolytes;

“(bb) drugs intended to maintain the equilibrium of water and minerals in the body;

“(cc) drugs intended for irrigation or reconstitution;

“(dd) anesthetics;

“(ee) anticoagulants;

“(ff) vasopressors; or

“(gg) sympathicomimetics;

“(xiv) the distribution of an intravenous prescription drug product that, by its formulation, is intended for the replenishment of fluids and electrolytes (such as sodium, chloride, and potassium) or calories (such as dextrose and amino acids);

“(xv) the distribution of an intravenous prescription drug product used to maintain the equilibrium of water and min-
erals in the body, such as dialysis solutions;

“(xvi) the distribution of a prescription drug product that is intended for irrigation or reconstitution, or sterile water, whether intended for such purposes or for injection;

“(xvii) the distribution of compressed medical gas; or

“(xviii)(I) the distribution of a product by a dispenser, or a wholesale distributor acting at the direction of the dispenser, to a repackager registered under section 510 for the purpose of repackaging the drug for use by that repackager or another health care entity that is under the dispenser’s ownership or control, so long as the dispenser retains ownership of the prescription drug product; and

“(II) the saleable or nonsaleable return by such repackager of such prescription drug product.

“(C) COMPRESSED MEDICAL GAS.—For purposes of subparagraph (B)(xvii), the term ‘compressed medical gas’ means any substance
in its gaseous or cryogenic liquid form that meets medical purity standards and has application in a medical or homecare environment, including oxygen and nitrous oxide.

“(22) TRANSACTION HISTORY.—The term ‘transaction history’ means a statement that—

“(A) includes the transaction information for each transaction conducted with respect to a prescription drug product beginning with the manufacturer or initial purchase distributor; and

“(B) is in paper or electronic form.

“(23) TRANSACTION INFORMATION.—The term ‘transaction information’ means—

“(A) the proprietary or established name or names of the prescription drug product;

“(B) the strength and dosage form of the prescription drug product;

“(C) the National Drug Code number of the prescription drug product;

“(D) the container size;

“(E) the number of containers;

“(F) the lot number of the prescription drug product;

“(G) the date of the transaction;
“(H) the business name and address of the
person from whom ownership is being trans-
ferred; and

“(I) the business name and address of the
person to whom ownership is being transferred.

“(24) TRANSACTION STATEMENT.—The ‘trans-
action statement’ is a statement, which states that
the manufacturer, repackager, wholesale distributor,
third-party logistics provider, or dispenser transferr-
ing ownership in a transaction—

“(A) is authorized;

“(B) received transaction information and
a transaction statement as required under sec-
tion 582 from the prior owner of the prescrip-
tion drug product;

“(C) did not knowingly and intentionally
ship an illegitimate prescription drug product;

“(D) did not knowingly and intentionally
provide false transaction information; and

“(E) did not knowingly and intentionally
alter the transaction history.

“(25) VERIFICATION AND VERIFY.—The terms
‘verification’ and ‘verify’—

“(A) mean determining whether the pre-
scription drug product identifier affixed to, or
imprinted upon, a package or homogeneous case of the prescription drug product corresponds to the standardized numerical identifier or lot number, and expiration date assigned to the prescription drug product by the manufacturer or the repackager, as applicable; and

“(B) include making the determination under subparagraph (A) using human-readable or machine-readable methods.

“(26) WHOLESALE DISTRIBUTOR.—The term ‘wholesale distributor’—

“(A) means a person engaged in wholesale distribution (as defined in section 583); and

“(B) excludes—

“(i) a manufacturer, a co-licensed partner of a manufacturer, or a third-party logistics provider, or a dispenser who does not engage in such wholesale distribution;

“(ii) a repackager engaged in such wholesale distribution; or

“(iii) the distribution of prescription drug product or an offer to distribute prescription drug product by an authorized repackager that has taken ownership or possession of the prescription drug product
and repacked the prescription drug product in accordance with the requirements of section 582(e).

“SEC. 582. REQUIREMENTS.

“(a) IN GENERAL.—

“(1) COMPLIANCE REQUIRED.—An entity that is a manufacturer, repackager, wholesale distributor, third-party logistics provider, or dispenser shall comply with the requirements of this section. If an entity meets the definition of more than one of the entities referred to in the preceding sentence, such entity shall comply with all applicable requirements of this section, but shall not be required to comply with duplicative requirements.

“(2) STANDARDS.—The Secretary shall, in consultation with other appropriate Federal officials, manufacturers, repackagers, wholesale distributors, third-party logistics providers, and dispensers, establish, by regulation, standards for the exchange of transaction history and transaction statement (in paper or electronic form) for purposes of complying with this section. The standards established under this paragraph shall be in accordance with a form developed by a widely recognized international standards development organization. In establishing such
standards, the Secretary shall consider the feasibility of establishing standardized documentation to be used by all members of the pharmaceutical distribution supply chain to convey the transaction history and transaction statement to the subsequent owner of a prescription drug product. The Secretary shall publish such standards not later than 180 days after the date of the enactment of the Safeguarding America’s Pharmaceuticals Act of 2013.

“(3) Waivers, exceptions, and exemptions.—Not later than one year after the date of the enactment of the Safeguarding America’s Pharmaceuticals Act of 2013, the Secretary shall promulgate a regulation to—

“(A) establish a process by which the Secretary may grant, at the request of an authorized manufacturer, repackager, wholesale distributor, or dispenser, a waiver from any of the requirements of this section—

“(i) if the Secretary determines that such requirements would result in an undue economic hardship; or

“(ii) for emergency medical reasons, including a public health emergency dec-
laration pursuant to section 319 of the Public Health Service Act;

“(B) establish a process, with respect to the prescription drug product identifier requirement under paragraph (2) of subsections (b), (c), (d), and (e) through which—

“(i) a manufacturer or repackager may request a waiver with respect to prescription drug products that are packaged in a container too small or otherwise unable to accommodate a label with sufficient space to bear the information required for compliance with such requirement; and

“(ii) the Secretary determines whether to waive such requirement; and

“(C) establish a process by which the Secretary may add the prescription drug products or transactions that are exempt from the requirements of this section.

“(4) GRANDFATHERED PERSONS AND PRESCRIPTION DRUG PRODUCTS.—

“(A) IN GENERAL.—Not later than one year after the date of the enactment of the Safeguarding America’s Pharmaceuticals Act of 2013, the Secretary shall specify, by regulation,
whether and under what circumstances the prescription drug product identifier requirement under paragraph (2) of subsections (b), (c), (d), and (e) shall apply to a prescription drug product that is in the supply chain or in a manufacturer’s inventory on the date of the enactment of the Safeguarding America’s Pharmaceuticals Act of 2013.

“(B) Third-party logistics provider licenses.—Until the date that is 1 year after the effective date of the third-party logistics provider licensing requirements under section 584, a third-party logistics provider shall be considered ‘licensed’ under section 581(6)(B) unless the Secretary has made a finding that the third-party logistics provider does not utilize good handling and distribution practices and publishes notice thereof.

“(C) Label changes.—Changes made to package labels solely to incorporate the prescription drug product identifier may be submitted to the Secretary in the annual report of an establishment, in accordance with section 314.70(d) of chapter 21, Code of Federal Regulations (or any successor regulation).
“(b) Manufacturer Requirements.—

“(1) Prescription drug product tracking.—

“(A) In general.—Beginning not later than January 1, 2015, a manufacturer shall—

“(i) prior to, or at the time of, each transaction in which such manufacturer transfers ownership of a prescription drug product—

“(I) until the date than is 5 years after the date of the enactment of the Safeguarding America’s Pharmaceuticals Act of 2013, provide the subsequent owner with the transaction history and a transaction statement in a single document in paper or electronic form; and

“(II) on or after such date, provide the subsequent owner with the transaction history and a transaction statement in electronic form; and

“(ii) maintain the transaction information for each such transaction for not less than 3 years after the date of the transaction.
“(B) Requests for information.—

Upon a request by the Secretary or other appropriate Federal or State official, in the event of a recall or for the purpose of investigating a suspect prescription drug product or an illegitimate prescription drug product, a manufacturer shall, not later than 2 business days after receiving the request or in such reasonable time as determined by the Secretary, provide to the Secretary or other official, the applicable transaction history and transaction statement for the prescription drug product.

“(2) Prescription drug product identifier.—Beginning not later than 5 years after the date of the enactment of the Safeguarding America’s Pharmaceuticals Act of 2013, a manufacturer shall affix or imprint a prescription drug product identifier on each package and homogenous case of a prescription drug product intended to be introduced in a transaction. Such manufacturer shall maintain the information in the prescription drug product identifier for such prescription drug product for not less than 3 years after the date of the transaction.

“(3) Authorized trading partners.—Beginning not later than January 1, 2015, a manufac-
turer shall ensure that each of its trading partners
is authorized.

“(4) List of Authorized Distributors of
Record.—Beginning not later than January 1,
2015, each manufacturer of a prescription drug
shall—

“(A) maintain a list of the authorized dis-
tributors of record of such drug at the cor-
porate offices of such manufacturer;

“(B) make such list publicly available, in-
cluding placement on the Internet Website of
such manufacturer; and

“(C) update such list not less than once
per quarter.

“(5) Verification.—Beginning not later than
January 1, 2015, a manufacturer shall implement
systems and processes to enable the manufacturer to
comply with the following requirements:

“(A) Suspect Prescription Drug Prod-
uct.—

“(i) In General.—Upon making a
determination that a prescription drug
product in the possession or control of the
manufacturer is a suspect prescription
drug product, or upon receiving a request
for verification from the Secretary that a
prescription drug product within the pos-
session or control of a manufacturer is a
suspect prescription drug product, a manu-
facturer shall promptly conduct an investi-
gation in coordination with trading part-
ers, as applicable, to determine whether
the prescription drug product is an illegit-
imate prescription drug product. Beginning
not later than 5 years after the date of the
enactment of the Safeguarding America’s
Pharmaceuticals Act of 2013, such investi-
gation shall include—

“(I) verifying the prescription
drug product at the package level;

“(II) validating any applicable
transaction history in the possession
of the manufacturer; and

“(III) otherwise investigating to
determine whether the prescription
drug product is an illegitimate pre-
scription drug product.

“(ii) CLEARED PRESCRIPTION DRUG
PRODUCT.—If the manufacturer deter-
mines that a suspect prescription drug
product is not an illegitimate prescription drug product, the manufacturer shall promptly notify the Secretary of such determination and such prescription drug product may be further distributed.

“(iii) Records.—A manufacturer shall keep records of its investigation of a suspect prescription drug product for not less than 3 years after the conclusion of the investigation.

“(B) Illegitimate Prescription Drug Product.—

“(i) In general.—Upon determining that a prescription drug product in the possession or control of a manufacturer is an illegitimate prescription drug product, the manufacturer shall—

“(I) quarantine such prescription drug product from prescription drug product intended for distribution; and

“(II) provide for the disposition of the illegitimate prescription drug product.

“(ii) Trading partner.—Upon determining that a prescription drug product
in the possession or control of a trading
partner is an illegitimate prescription drug
product, the manufacturer shall take rea-
sonable steps to assist a trading partner to
provide for the disposition of the illegiti-
mate prescription drug product.

“(iii) MAKING A NOTIFICATION.—
Upon determining that a prescription drug
product in the possession or control of the
manufacturer is an illegitimate prescrip-
tion drug product, the manufacturer shall
notify the Secretary of such determination
not later than 24 hours after making such
determination. The Secretary shall deter-
mine whether additional trading partner
notification is appropriate.

“(iv) RESPONDING TO A NOTIFICA-
TION.—Upon the receipt of a notification
from the Secretary that a determination
has been made that a prescription drug
product is an illegitimate prescription drug
product, a manufacturer shall—

“(I) identify all illegitimate pre-
scription drug products that are sub-
ject to such notification and in the
possession or control of the manufacturer, including any prescription drug product that is subsequently received; and

“(II) perform the activities described in clause (i).

“(v) RECORDS.—A manufacturer shall keep records of the disposition of an illegitimate prescription drug product for not less than 3 years after the conclusion of the disposition.

“(C) ELECTRONIC DATABASE.—A manufacturer may satisfy the requirements of this paragraph through the use of a secure electronic database developed and operated by the manufacturer or another entity. The owner of such database shall establish the requirements and processes to respond to requests and may provide for data access to other members of the pharmaceutical distribution supply chain, as appropriate. The development and operation of such a database shall not relieve a manufacturer of the requirement under this paragraph to respond to a verification request submitted
by means other than a secure electronic database.

“(D) RETURNED PRESCRIPTION DRUG PRODUCT.—Beginning not later than 5 years after the date of the enactment of the Safeguarding America’s Pharmaceuticals Act of 2013, upon receipt of a returned prescription drug product that the manufacturer intends to further distribute, before further distributing such prescription drug product, the manufacturer shall—

“(i) verify the prescription drug product identifier for each sealed homogeneous case of such prescription drug product; or

“(ii) if such prescription drug product is not in a sealed homogeneous case, verify the prescription drug product identifier on each package.

“(c) WHOLESALE DISTRIBUTOR REQUIREMENTS.—

“(1) PRESCRIPTION DRUG PRODUCT TRACING.—

“(A) IN GENERAL.—Beginning not later than April 1, 2015, a wholesale distributor shall—
“(i) not accept ownership of a prescription drug product unless the previous owner prior to, or at the time of, the transaction provides the applicable transaction history and a transaction statement for the prescription drug product;

“(ii) subject to clause (iv), prior to, or at the time of, each transaction in which the wholesale distributor transfers ownership of a prescription drug product—

“(I) in the case that the wholesale distributor purchased the prescription drug product directly from the manufacturer, the exclusive distributor of the manufacturer, or a re-packer that purchased directly from the manufacturer, provide the subsequent owner with transaction history and a transaction statement for the prescription drug product—

“(aa) if the subsequent owner is a dispenser, on a single document in paper or electronic form; or
“(bb) if the subsequent owner is a wholesale distributor, through any combination of self-generated paper, electronic data, or manufacturer-provided information on the product package;

“(II) in the case that the wholesale distributor did not purchase the prescription drug product as described in subclause (I)—

“(aa) provide the subsequent owner with the transaction history and a transaction statement beginning with the wholesale distributor that did so purchase the prescription drug product in paper or electronic form; or

“(bb) pursuant to a written agreement between the wholesale distributor and a dispenser, maintain the transaction history and transaction statement on behalf of the dispenser and if requested by the dispenser, provide the transaction history and
transaction statement to the dis-

penser in paper or electronic

form in a timely manner so as to

permit the dispenser to comply

with requests pursuant to sub-

section (d)(1)(D);

“(iii) maintain the transaction infor-

mation for each transaction described in

clauses (i) and (ii) for not less than 3

years after the transaction; and

“(iv) on or after the date that is 5

years after the date of the enactment of

the Safeguarding America’s Pharma-

caceuticals Act of 2013, provide the trans-

action history and transaction statement in

electronic form.

“(B) INCLUSION OF LOT NUMBER IN

TRANSACTION HISTORY.—Until the date that is

5 years after the date of the enactment of the

Safeguarding America’s Pharmaceuticals Act of

2013, the transaction history provided by a

wholesale distributor under this paragraph shall

not be required to include the lot number of the

product or the initial date of the transaction

from the manufacturer (as such terms are used
in subparagraphs (F) and (G) of section 581(23)).

“(C) RETURNS EXCEPTION.—

“(i) SALEABLE RETURNS.—Notwithstanding subparagraph (A), a wholesale distributor may—

“(I) accept returned prescription drug product without a transaction history from a dispenser or repackager; and

“(II) distribute such returned prescription drug product with a transaction history that begins with the wholesale distributor that so accepted the returned product.

“(ii) NONSALEABLE RETURNS.—A wholesale distributor may return a non-saleable prescription drug to the manufacturer or repackager, to the wholesale distributor from whom such prescription drug was purchased, or to a person acting on behalf of such a person, including a returns processor, without providing the information required under subparagraph (A).
“(D) Requests for information.—
Upon a request by the Secretary or other appropriate Federal or State official, in the event of a recall or for the purpose of investigating a suspect prescription drug product or an illegitimate prescription drug product a wholesale distributor shall, not later than 2 business days after receiving the request or in such other reasonable time as determined by the Secretary, provide the applicable transaction history and transaction statements for the prescription drug product.

“(2) Prescription drug product identifier.—Beginning not later than 7 years after the date of the enactment of the Safeguarding America’s Pharmaceuticals Act of 2013, a wholesale distributor may engage in transactions involving a prescription drug product only if such prescription drug product is encoded with a prescription drug product identifier, except as provided in subsection (a)(4).

“(3) Authorized trading partners.—Beginning not later than January 1, 2015, a wholesale distributor shall ensure that each of its trading partners is authorized.
“(4) VERIFICATION.—Beginning not later than April 1, 2015, a wholesale distributor shall imple-
ment systems to enable the wholesale distributor to comply with the following requirements:

“(A) SUSPECT PRESCRIPTION DRUG PROD-
uct.—

“(i) IN GENERAL.—Upon making a determination that a prescription drug product in the possession or control of the wholesale distributor is a suspect prescrip-
tion drug product, or upon receiving a re-
quest for verification from the Secretary that a prescription drug product within the possession or control of a wholesale dis-
tributor is a suspect prescription drug product, a wholesale distributor shall promptly conduct an investigation to deter-
mine whether the prescription drug prod-
uct is an illegitimate prescription drug product. Beginning not later than 7 years after the date of the enactment of the Safeguarding America’s Pharmaceuticals Act of 2013, such investigation shall in-
clude—
“(I) verifying a package of the prescription drug product;

“(II) validating any applicable transaction history in the possession of the wholesale distributor; and

“(III) otherwise investigating to determine whether the prescription drug product is an illegitimate prescription drug product.

“(ii) CLEARED PRESCRIPTION DRUG PRODUCT.—If the wholesale distributor determines that a suspect prescription drug product is not an illegitimate prescription drug product, the wholesale distributor shall promptly notify the Secretary of such determination and such prescription drug product may be further distributed.

“(iii) RECORDS.—A wholesale distributor shall keep records of its investigation of a suspect prescription drug product for not less than 3 years after the conclusion of the investigation.

“(B) ILLEGITIMATE PRESCRIPTION DRUG PRODUCT.—
“(i) IN GENERAL.—Upon receiving notice that a manufacturer of a prescription drug product has determined that a prescription drug product in the possession or control of a wholesale distributor is an illegitimate prescription drug product, the wholesale distributor shall—

“(I) quarantine such prescription drug product within the possession or control of the wholesale distributor from prescription drug product intended for distribution; and

“(II) provide for the disposition of the illegitimate prescription drug product within the possession or control of the wholesale distributor.

“(ii) TRADING PARTNER.—Upon determining that a prescription drug product in the possession or control of a trading partner is an illegitimate prescription drug product, the wholesale distributor shall take reasonable steps to assist a trading partner to provide for the disposition of the illegitimate prescription drug product.
“(iii) Making a Notification.—Upon determining that a prescription drug product in the possession or control of the wholesale distributor is an illegitimate prescription drug product, the wholesale distributor shall notify the Secretary of such determination not later than 24 hours after making such determination. The Secretary shall determine whether additional trading partner notification is appropriate.

“(iv) Responding to a Notification.—Upon the receipt of a notification from the Secretary that a determination has been made that a prescription drug product is an illegitimate prescription drug product, a wholesale distributor shall—

“(I) identify all illegitimate prescription drug products subject to such notification that are in the possession or control of the wholesale distributor, including any such prescription drug product that is subsequently received; and

“(II) perform the activities described in clause (i).
“(v) Records.—A wholesale distributor shall keep records of the disposition of an illegitimate prescription drug product for not less than 3 years after the conclusion of the disposition.

“(C) Electronic database.—A wholesale distributor may satisfy the requirements of this paragraph through the use of a secure electronic database developed and operated by the manufacturer or another entity. The owner of such database shall establish the requirements and processes to respond to requests and may provide for data access to other members of the pharmaceutical distribution supply chain, as appropriate. The development and operation of such a database shall not relieve a wholesale distributor of the requirement under this paragraph to respond to a verification request submitted by means other than a secure electronic database.

“(D) Returned prescription drug product.—Beginning not later than 7 years after the date of the enactment of the Safeguarding America’s Pharmaceuticals Act of 2013, upon receipt of a returned prescription
drug product that the wholesale distributor intends to further distribute, before further distributing such prescription drug product, the wholesale distributor shall—

“(i) verify the prescription drug product identifier for each sealed homogeneous case of such prescription drug product; or

“(ii) if such prescription drug product is not in a sealed homogeneous case, verify the prescription drug product identifier on each package.

“(d) DISPENSER REQUIREMENTS.—

“(1) PRESCRIPTION DRUG PRODUCT TRACING.—

“(A) IN GENERAL.—Beginning not later than July 1, 2015, a dispenser—

“(i) shall not accept ownership of a prescription drug product, unless the previous owner prior to, or at the time of, the transaction, provides transaction history and a transaction statement;

“(ii) prior to, or at the time of, each transaction in which the dispenser transfers ownership of a prescription drug product (but not including dispensing to a pa-
tient or returns) shall provide the subsequent owner with transaction history and a transaction statement for the prescription drug product, except that the requirements of this clause shall not apply to sales by a dispenser to another dispenser to fulfill a specific patient need; and

“(iii) shall maintain transaction information for a period of not less than 3 years after the date of the transaction.

“(B) AGREEMENTS WITH THIRD PARTIES.—A dispenser may enter into a written agreement with a third party, including an authorized wholesale distributor, under which the third party confidentially maintains the transaction information required to be maintained under this subsection on behalf of the dispenser. If a dispenser enters into such an agreement, the dispenser shall maintain a copy of the written agreement.

“(C) RETURNS EXCEPTION.—

“(i) SALEABLE RETURNS.—Notwithstanding subparagraph (A)(ii), a dispenser may return prescription drug product to the trading partner from which the dis-
penser obtained the prescription drug
product without providing the information
required under such subparagraph.

“(ii) NONSALEABLE RETURNS.—Not-
withstanding subparagraph (A)(ii), a dis-
penser may return a nonsaleable prescrip-
tion drug to the manufacturer or repack-
ager, to the wholesale distributor from
whom such prescription drug was pur-
chased, to a returns processor, or to a per-
son acting on behalf of such persons with-
out providing the information required
under such subparagraph.

“(D) REQUESTS FOR INFORMATION.—
Upon a request by the Secretary or other ap-
propriate Federal or State official, in the event
of a recall or for the purpose of investigating a
suspect prescription drug product or an illegit-
imate prescription drug product—

“(i) a dispenser shall not later than 2
business days after receiving the request or
in another such reasonable time as deter-
mined by the Secretary, provide the appli-
cable transaction history and transaction
statement which the dispenser received
from the previous owner;

“(ii) the information provided by the
dispenser under clause (i) is not required
to include the lot number of the product,
the initial date of the transaction, or the
initial date of the shipment from the manu-
ufacturer unless such information was pro-
vided electronically by the previous owner,
manufacturer, or wholesale distributor to
the dispenser; and

“(iii) a dispenser may respond to the
request by providing the paper documenta-
tion received from the previous owner or
by providing electronic information.

“(2) Prescription Drug Product Identifier.—Beginning not later than 8 years after the
date of the enactment of the Safeguarding America’s
Pharmaceuticals Act of 2013, a dispenser may en-
gage in transactions involving a prescription drug
product only if such prescription drug product is en-
coded with a prescription drug product identifier, ex-
cept as provided in subsection (a)(4).

“(3) Authorized Trading Partners.—Be-
beginning not later than January 1, 2015, a dispenser
shall ensure that each of its trading partners is authorized.

“(4) VERIFICATION.—Beginning not later than January 1, 2015, a dispenser shall implement systems to enable the dispenser to comply with the following requirements:

“(A) SUSPECT PRESCRIPTION DRUG PRODUCT.—

“(i) IN GENERAL.—Upon making a determination that a prescription drug product in the possession or control of the dispenser is a suspect prescription drug product, or upon receiving a request for verification from the Secretary that a prescription drug product within the possession or control of a dispenser is a suspect prescription drug product, a dispenser shall promptly conduct an investigation to determine whether the prescription drug product is an illegitimate prescription drug product. Such investigation shall include—

“(I) verifying whether the lot number of a suspect prescription drug product corresponds with the lot num-
(II) beginning 8 years after the date of the enactment of the Safeguarding America’s Pharmaceuticals Act of 2013, verifying that the product identifier of at least 3 packages or 10 percent of such suspect prescription drug product, whichever is greater, or all packages, if there are fewer than 3, corresponds with the prescription drug product identifier for such product;

(III) validating any applicable transaction history in the possession of the dispenser; and

(IV) otherwise investigating to determine whether the prescription drug product is an illegitimate prescription drug product.

(ii) CLEARED PRESCRIPTION DRUG PRODUCT.—If the dispenser makes the determination that a suspect prescription drug product is not an illegitimate prescription drug product, the dispenser shall
promptly notify the Secretary of such de-
termination and such prescription drug
product may be further dispensed.

“(iii) RECORDS.—A dispenser shall
keep records of its investigation of a sus-
pect prescription drug product for not less
than 3 years after the conclusion of the in-
vestigation.

“(B) ILLEGITIMATE PRESCRIPTION DRUG
PRODUCT.—

“(i) IN GENERAL.—Upon receiving
notice that a manufacturer of a prescrip-
tion drug product has determined that a
prescription drug product in the possession
or control of a dispenser is an illegitimate
prescription drug product, the dispenser
shall—

“(I) quarantine such prescription
drug product within the possession or
control of the dispenser from prescrip-
tion drug product intended for dis-
tribution; and

“(II) provide for the disposition
of the illegitimate prescription drug
product within the possession or control of the dispenser.

“(ii) Trading Partners.—Upon determining that a prescription drug product in the possession or control of a trading partner is an illegitimate prescription drug product, the dispenser shall take reasonable steps to assist a trading partner to provide for the disposition of the illegitimate prescription drug product.

“(iii) Making a Notification.—Upon determining that a prescription drug product in the possession or control of the dispenser is an illegitimate prescription drug product, the dispenser shall notify the Secretary of such determination not later than 24 hours after making such determination. The Secretary shall determine whether additional trading partner notification is appropriate.

“(iv) Responding to a Notification.—Upon the receipt of a notification from the Secretary that a determination has been made that a prescription drug
product is an illegitimate prescription drug product, a dispenser shall—

“(I) identify all illegitimate prescription drug products that are subject to such notification and in the possession or control of the dispenser, including any such prescription drug product that is subsequently received; and

“(II) perform the activities described in clause (i).

“(v) RECORDS.—A dispenser shall keep records of the disposition of an illegitimate prescription drug product for not less than 3 years after the conclusion of the disposition.

“(C) ELECTRONIC DATABASE.—A dispenser may satisfy the requirements of this paragraph through the use of a secure electronic database developed and operated by the manufacturer or another entity. The owner of such database shall establish the requirements and processes to enable responding to requests and may provide for data access to other members of the pharmaceutical distribution supply
chain, as appropriate. The development and operation of such a database shall not relieve a dispenser of the requirement under this paragraph to respond to a verification request submitted by means other than a secure electronic database.

“(e) REPACKAGER REQUIREMENTS.—

“(1) PRESCRIPTION DRUG PRODUCT TRACING.—

“(A) IN GENERAL.—Beginning not later than April 1, 2015, with respect to a prescription drug product received by a repackager from a wholesale distributor, and beginning not later than January 1, 2015, with respect to any other prescription drug product, a repackager shall—

“(i) not accept ownership of a prescription drug product unless the previous owner, prior to, or at the time of, the transaction, provides transaction history and a transaction statement for the prescription drug product;

“(ii) prior to, or at the time of, each transaction in which the repackager transfers ownership of a prescription drug prod-
uct, provide the subsequent owner with
transaction history and a transaction state-
ment;

“(iii) maintain the transaction infor-
mination for each transaction described in
clause (i) or (ii) for not less than 3 years
after the transaction; and

“(iv) maintain records that allow the
repackager to associate the prescription
drug product identifier the repackager af-
fixes or imprints with the prescription drug
product identifier assigned by the original
manufacturer of the prescription drug
product.

“(B) RETURNS EXCEPTION.—Notwith-
standing subparagraph (A)(ii), a repackager
may return prescription drug product to the
trading partner from whom the repackager ob-
tained the prescription drug product without
providing the information required under such
subparagraph.

“(C) REQUESTS FOR INFORMATION.—
Upon a request by the Secretary or other ap-
propriate Federal or State official, in the event
of a recall or for the purpose of investigating a
suspect prescription drug product or an illegitimate prescription drug product, a repackager shall, not later than 2 business days after receiving the request or in such other reasonable time as determined by the Secretary, provide the applicable transaction history and transaction statement for the prescription drug product.

“(2) Prescription drug product identifier.—Beginning not later than 6 years after the date of the enactment of the Safeguarding America’s Pharmaceuticals Act of 2013, a repackager—

“(A) shall affix or imprint a prescription drug product identifier to each package and homogenous case of prescription drug product intended to be introduced in a transaction;

“(B) shall maintain the prescription drug product identifier for such prescription drug product for not less than 3 years after the date of the transaction; and

“(C) may engage in transactions involving a prescription drug product only if such prescription drug product is encoded with a prescription drug product identifier except as provided in subsection (a)(4).
“(3) AUTHORIZED TRADING PARTNERS.—Beginning on January 1, 2015, a repackager shall ensure that each of its trading partners is authorized.

“(4) VERIFICATION.—Beginning not later than January 1, 2015, a repackager shall implement systems to enable the repackager to comply with the following requirements:

“(A) SUSPECT PRESCRIPTION DRUG PRODUCT.—

“(i) IN GENERAL.—Upon making a determination that a prescription drug product in the possession or control of the repackager is a suspect prescription drug product, or upon receiving a request for verification from the Secretary that a prescription drug product within the possession or control of a repackager is a suspect prescription drug product, a repackager shall promptly conduct an investigation to determine whether the prescription drug product is an illegitimate prescription drug product, including—

“(I) beginning not later than 6 years after the date of the enactment of the Safeguarding America’s Pharm-
maceuticals Act of 2013, verifying the

prescription drug product at the pack-
age level;

“(II) validating any applicable

transaction information in the posses-
sion of the repackager; and

“(III) otherwise investigating to
determine whether the prescription
drug product is an illegitimate pre-
scription drug product.

“(ii) Cleared Prescription Drug

Product.—If the repackager determines

that a suspect prescription drug product is

not an illegitimate prescription drug prod-
uct, the repackager shall promptly notify
the Secretary of such determination and
such prescription drug product may be fur-
ther distributed.

“(iii) Records.—A repackager shall
keep records of its investigation of a sus-
pect prescription drug product for not less
than 3 years after the conclusion of the in-
vestigation.

“(B) Illegitimate Prescription Drug

Product.—
“(i) IN GENERAL.—Upon receiving notice that a manufacturer of a prescription drug product has determined that a prescription drug product in the possession or control of a repackager is an illegitimate prescription drug product, the repackager shall—

“(I) quarantine such prescription drug product within the possession or control of the repackager from prescription drug product intended for distribution; and

“(II) provide for the disposition of the illegitimate prescription drug product within the possession or control of the repackager.

“(ii) TRADING PARTNER.—Upon determining that a prescription drug product in the possession or control of a trading partner is an illegitimate prescription drug product, the repackagers shall take reasonable steps to assist the trading partner to provide for the disposition of the illegitimate prescription drug product.
“(iii) Making a Notification.—
Upon determining that a prescription drug product in the possession or control of the repackager is an illegitimate prescription drug product, the repackager shall notify the Secretary of such determination not later than 24 hours after making such determination. The Secretary shall determine whether additional trading partner notification is appropriate.

“(iv) Responding to a Notification.—Upon the receipt of a notification from the Secretary that a determination has been made that a prescription drug product is an illegitimate prescription drug product, a repackager shall—

“(I) identify all illegitimate prescription drug products that are subject to such notification and in the possession or control of the repackager, including any such prescription drug product that is subsequently received; and

“(II) perform the activities described in clause (i).
“(v) Records.—A repackager shall keep records of the disposition of an illegitimate prescription drug product for not less than 3 years after the conclusion of the disposition.

“(C) Electronic Database.—A repackager may satisfy the requirements of this paragraph through the use of a secure electronic database developed and operated by the manufacturer or another entity. The owner of such database shall establish the requirements and processes to respond to requests and may provide for data access to other members of the pharmaceutical distribution supply chain, as appropriate. The development and operation of such a database shall not relieve a repackager of the requirement under this paragraph to respond to a verification request submitted by means other than a secure electronic database.

“(D) Returned Prescription Drug Product.—Beginning not later than 6 years after the date of the enactment of the Safeguarding America’s Pharmaceuticals Act of 2013, upon receipt of a returned prescription drug product that the repackager intends to
further distribute, before further distributing such prescription drug product, the repackager shall—

“(i) verify the prescription drug product identifier for each sealed homogeneous case of such prescription drug product; or

“(ii) if such prescription drug product is not in a sealed homogeneous case, verify the prescription drug product identifier on each package.

“(f) Third-Party Logistics Provider Requirements.—

“(1) Authorized Trading Partners.—Beginning on January 1, 2015, a third-party logistics provider shall ensure that each of its trading partners is authorized.

“(2) Verification.—Beginning not later than January 1, 2015, a third-party logistics provider shall implement systems to enable the third-party logistics provider to comply with the following requirements:

“(A) Suspect Prescription Drug Product.—

“(i) In General.—Upon making a determination that a prescription drug
product in the possession or control of a
third-party logistics provider is a suspect
prescription drug product, a third-party lo-
gistics provider shall promptly notify the
owner of such prescription drug product of
the need to conduct an investigation to de-
terminate whether the prescription drug
product is an illegitimate prescription drug
product.

“(ii) Cleared prescription drug
product.—If the owner of the prescrip-
tion drug product notifies the third-party
logistics provider of the determination that
a suspect prescription drug product is not
an illegitimate prescription drug product,
such prescription drug product may be fur-
ther distributed.

“(iii) Records.—A third-party logis-
tics provider shall keep records of the ac-
tivities described in clauses (i) and (ii)
with respect to a suspect prescription drug
product for not less than 3 years after the
conclusion of the investigation.

“(B) Illegitimate prescription drug
product.—
“(i) IN GENERAL.—Upon receiving notice that a manufacturer of a prescription drug product has determined that a prescription drug product in the possession or control of a third-party logistics provider is an illegitimate prescription drug product, the third-party logistics provider shall—

“(I) quarantine such prescription drug product within the possession or control of the third-party logistics provider from prescription drug product intended for distribution;

“(II) promptly notify the owner of such prescription drug product of the need to provide for the disposition of such prescription drug product; and

“(III) promptly transfer possession of the prescription drug product to the owner of such prescription drug product to provide for the disposition of the prescription drug product.

“(ii) MAKING A NOTIFICATION.—Upon determining that a prescription drug product in the possession or control of the
third-party logistics provider is an illegitimate prescription drug product, the third-party logistics provider shall notify the Secretary not later than 24 hours after making such determination. The Secretary shall determine whether additional trading partner notification is appropriate.

“(iii) RESPONDING TO A NOTIFICATION.—Upon the receipt of a notification from the Secretary, a third-party logistics provider shall—

“(I) identify all illegitimate prescription drug products subject to such notification that are in the possession or control of the third-party logistics provider, including any such prescription drug product that is subsequently received; and

“(II) perform the activities described in clause (i).

“(iv) RECORDS.—A third-party logistics provider shall keep records of the activities described in clauses (i) and (ii) with respect to an illegitimate prescription
drug product for not less than 3 years
after the conclusion of the disposition.

“(g) DROP SHIPMENTS.—This section does not apply
to any entity, notwithstanding its status as a wholesale
distributor or repackager, or other status that is not in-
volved in the physical handling, distribution, or storage of
a prescription drug product. For purposes of this sub-
section, facilitating the distribution of a prescription drug
product by providing various administrative services, in-
cluding processing of orders and payments, shall not, by
itself, be construed as being involved in the handling, dis-
tribution, or storage of a prescription drug product.”

SEC. 3. ENHANCED DRUG DISTRIBUTION SECURITY.

(a) PILOT PROJECTS.—

(1) IN GENERAL.—Not later than 2 years after
the date of the enactment of this Act, the Secretary
shall establish one or more pilot projects in coordi-
nation with manufacturers, repackagers, wholesale
distributors, third-party logistics providers, and dis-
pensers to explore and evaluate methods to enhance
the safety and security of the pharmaceutical dis-
tribution supply chain.

(2) CONTENT.—
(A) IN GENERAL.—The Secretary shall ensure that the pilot projects under paragraph (1) collectively—

(i) reflect the diversity of the pharmaceutical distribution supply chain; and

(ii) include participants representative of every sector within the pharmaceutical distribution supply chain, including participants representative of small businesses.

(B) PROJECT DESIGN.—The pilot projects shall be designed to—

(i) utilize the prescription drug product identifier for tracing of a prescription drug product, which utilization may include—

(I) verification of the prescription drug product identifier of a prescription drug product; and

(II) the use of aggregation and inference;

(ii) improve the technical capabilities of each sector within the pharmaceutical supply chain to comply with systems and processes needed to utilize the prescription
drug product identifiers to enhance tracing
of a prescription drug product; and

(iii) conduct such other activities as
the Secretary determines appropriate to
explore and evaluate methods to enhance
the safety and security of the pharma-
ceutical distribution supply chain.

(b) Public Meetings.—

(1) In General.—Not later than 6 months
after the date of the enactment of this Act, and at
least every 6 months thereafter until the submission
of the report required by subsection (e)(2), the Sec-
retary shall hold a public meeting to enhance the
safety and security of the pharmaceutical distribu-
tion supply chain. In conducting such meetings, the
Secretary shall take all measures reasonable and
practicable to ensure the protection of confidential
commercial information and trade secrets.

(2) Content.—In conducting meetings under
this subsection, the Secretary shall seek to address,
in at least one such meeting, each of the following
topics:

(A) Best practices in each of the sectors
within the pharmaceutical distribution supply
chain to implement the requirements of section
582 of the Federal Food, Drug, and Cosmetic Act, as added by section 2.

(B) The costs and benefits of implementation of such section 582, including the impact on each pharmaceutical distribution supply chain sector and on public health.

(C) Whether additional electronic traceability requirements, including tracing of prescription drug product at the package level, are feasible, cost effective, overly burdensome on small businesses, and needed to protect public health.

(D) The systems and processes needed to utilize the prescription drug product identifiers to enhance tracing of prescription drug product at the package level, including allowing for verification, aggregation, and inference by each sector within the pharmaceutical distribution supply chain for cases, pallets, totes, and other containers of aggregated prescription drug product as necessary.

(E) The technical capabilities and legal authorities, if any, needed to establish an electronic system that provides for enhanced trac-
ing of prescription drug product at the package level.

(F) The impact that the requirements, systems, processes, capabilities, and legal authorities referred to in subparagraphs (C), (D), and (E) would have on patient safety, the drug supply, cost and regulatory burden, the timeliness of patient access to prescription drugs, and small businesses.

(c) Study of the Pharmaceutical Distribution Supply Chain.—

(1) IN GENERAL.—The Comptroller General of the United States shall conduct a study to examine implementation of the requirements established under subchapter H of chapter V of the Federal Food, Drug, and Cosmetic Act, as added by section 2, in order to inform the regulations promulgated under this section.

(2) CONSIDERATION.—In conducting the study under this subsection, the Comptroller General shall provide for stakeholder input and shall consider the following:

(A) The implementation of the requirements established under such subchapter H with respect to—
(i) the ability of the health care system collectively to maintain patient access to medicines;

(ii) the scalability of such requirements, including with respect to prescription drug product lines; and

(iii) the capability of different sectors within the pharmaceutical distribution supply chain, including small businesses, to affix and utilize the prescription drug product identifier.

(B) The need for additional legal authorities and activities to address additional gaps in the pharmaceutical distribution supply chain, if any, after the implementation of the requirements established under such subchapter H with respect to—

(i) the systems and processes needed to enhance tracing of prescription drug product at the package level, including the use and evaluation of verification, aggregation, and inference by each sector within the pharmaceutical distribution supply chain as necessary;
(ii) the impact, feasibility, and cost effectiveness that additional requirements pursuant to this section would have on each pharmaceutical distribution supply chain sector and the public health; and

(iii) the systems and processes needed to enhance interoperability among trading partners.

(C) Risks to the security and privacy of data collected, maintained, or exchanged pursuant to the requirements established under such subchapter H.

(d) Small Dispensers.—

(1) In general.—Not later than 10 years after the date of the enactment of this Act, the Secretary shall enter into a contract with a private, independent consulting firm with relevant expertise to conduct a technology and software study on the feasibility of dispensers that have 25 or fewer full-time employees conducting interoperable, electronic tracing of prescription drug products at the package level.

(2) Condition.—As a condition of the award of a contract under paragraph (1), the private independent consulting firm awarded such contract shall
agree to consult with dispensers that have 25 or fewer full-time employees when conducting the study under such subparagraph.

(3) **STUDY CONTENT.**—The study conducted under paragraph (1) shall assess whether, with respect to conducting interoperable, electronic tracing of prescription drug products at the package level, the necessary hardware and software—

(A) is readily accessible to such dispensers;

(B) is not prohibitively expensive to obtain, install, and maintain for such dispensers; and

(C) can be integrated into business practices, such as interoperability with wholesale distributors, for such dispensers.

(4) **PUBLICATION.**—The Secretary shall publish—

(A) the statement of work for the study conducted under paragraph (1) for public comment not later than 30 days before commencing the study; and

(B) the final version of such study for public comment not later than 30 days after such study is completed.

(5) **REPORT TO CONGRESS.**—Not later than 30 days after the date on which the study conducted
under paragraph (1) is completed, the Secretary
shall submit to the Committee on Energy and Com-
merce of the House of Representatives and the Com-
mittee on Health, Education, Labor, and Pensions
of the Senate, a report on the findings of the study
and any recommendations to improve the technology
and software available to small dispensers for pur-
poses of conducting electronic, interoperable tracing
of prescription drug products at the package level.

(6) Public Meeting.—Not later than 180
days after the date on which the study conducted
under paragraph (1) is completed, the Secretary
shall hold a public meeting at which members of the
public, including stakeholders, may present their
views on the study.

(e) Reports.—

(1) GAO Report.—Not later than 12 years
after the date of the enactment of this Act, the
Comptroller General shall submit to the Committee
on Energy and Commerce of the House of Rep-
resentatives and the Committee on Health, Edu-
cation, Labor, and Pensions of the Senate a report
on the results of the study conducted under sub-
section (e).
(2) FDA REPORT.—Not later than 12 years after the date of the enactment of this Act, the Secretary shall submit to the Committee on Energy and Commerce of the House of Representatives and the Committee on Health, Education, Labor, and Pensions of the Senate a report on the results of the pilot program conducted under subsection (a), taking into consideration—

(A) the comments received during the public meetings conducted under subsection (b); and

(B) the results of the study conducted, and the public comments received during the public meeting held, under subsection (d).

(f) ESTABLISHMENT OF ADDITIONAL REQUIREMENTS.—

(1) IN GENERAL.—Notwithstanding any other provision of this Act, including the amendments made by this Act, not earlier than January 1, 2027, and not later than March 1, 2027, the Secretary shall issue proposed regulations that establish additional requirements to prevent a suspect product, illegitimate product, or a product that is counterfeit, stolen, diverted, or otherwise unfit for distribution
from entering into or being further distributed in
the supply chain, including—

(A) requirements related to the use of
interoperable electronic systems and tech-
nologies for enhanced tracing of prescription
drug product at the package level, which may
include verification of the prescription drug
product identifier of a package of prescription
drug product and enhanced verification of sale-
able returns;

(B) requirements related to the use of ad-
ditional prescription drug product identifiers or
prescription drug product identifier technology
that meet the standards developed under sec-
tion 582(a)(2) of the Federal Food, Drug, and
Cosmetic Act, as added by section 2;

(C) requirements related to the use of ag-
gregation, inference, and other methods, which
shall permit the use of aggregation and infer-
ence for cases, pallets, totes, and other con-
tainers of aggregated prescription drug prod-
ucts by each sector of the pharmaceutical dis-
tribution supply chain, if determined to be nec-
essary components of the systems and tech-
nologies referred to in subparagraph (A); and
(D) other data transmission and maintenance requirements and interoperability standards.

(2) FLEXIBILITY.—The requirements described in paragraph (1) shall provide for flexibility for a member of the pharmaceutical supply chain, by—

(A) with respect to dispensers, allowing a dispenser to enter into a written agreement with a third party, including an authorized wholesale distributor, under which—

(i) the third party confidentially maintains any information required to be maintained under such requirements for the dispenser; and

(ii) the dispenser maintains a copy of the written agreement and is not relieved of the other obligations of the dispenser under such requirements;

(B) establishing a process by which an authorized manufacturer, repackager, wholesale distributor, or dispenser may request a waiver from any such requirements if the Secretary determines that such requirements would result in an undue economic hardship on the manufacturer, wholesale distributor, or dispenser;
(C) not requiring the adoption of specific business systems by a member of the pharmaceutical supply chain for the maintenance and transmission of prescription drug product tracing data; and

(D) prescribing alternative methods of compliance for small businesses, as specified in paragraph (4).

(3) CONSIDERATIONS.—In issuing proposed regulations under paragraph (1), the Secretary shall consider—

(A) the results of, and public comments resulting from, the pilot project conducted under subsection (a);

(B) the public meetings held under subsection (b) and public comments from such meetings;

(C) the studies conducted under subsections (c) and (d);

(D) the reports submitted under subsection (e);

(E) the public health benefits of such regulations compared with the cost of compliance with the requirements contained in such regula-
tions, including with respect to entities of varying sizes and capabilities; and

(F) the diversity of the pharmaceutical distribution supply chain by providing appropriate flexibility for each sector in the supply chain, including small businesses.

(4) SMALL BUSINESS PROTECTION.—The Secretary, taking into consideration the study conducted under paragraph (d), shall, if the Secretary determines that the requirements established pursuant to paragraph (1) would result in an undue economic hardship on small businesses, provide for alternative methods of compliance with any such requirement by small businesses, including—

(A) establishing timelines for such compliance (including compliance by dispensers with 25 or fewer full-time employees) that do not impose undue economic hardship for small businesses, including dispensers with respect to which the study concluded has insufficient hardware and software to conduct interoperable, electronic tracing of prescription drug products at the package level; and
(B) establishing a process by which a dis-
penser may request a waiver from any such re-
quirement.

(5) REGULATIONS.—In issuing regulations to
carry out this subsection, the Secretary shall—

(A) issue a notice of proposed rulemaking
that includes a copy of the proposed rule;

(B) provide for a period of not less than
60 days for comments on the proposed rule;
and

(C) provide for an effective date of the
final rule that is 2 years after the date on
which such final rule is published.

(6) SUNSET.—The requirements regarding the
provision and receipt of transaction history and
transaction statements under section 582 of the
Federal Food, Drug, and Cosmetic Act, as added by
section 2, shall cease to be effective on the date on
which the regulations issued under this section are
fully implemented.

(g) DEFINITIONS.—In this section:

(1) The terms defined in section 581 of the
Federal Food, Drug, and Cosmetic Act, as added by
section 2, shall have the same meanings in this sec-
tion as such terms are given in such section 581.
(2) The term “Secretary” means the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs.

SEC. 4. NATIONAL STANDARDS FOR WHOLESALE DISTRIBUTORS.

(a) Standards.—Chapter V of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 351 et seq.) is amended—

(1) in section 503 (21 U.S.C. 353), by striking “(e)(1)(A)” and all that follows through “(3) For the purposes of this subsection and subsection (d)—” and inserting the following: “(e) For purposes of subsection (d)—”;

(2) in section 503(e) (21 U.S.C. 353(e)), by redesignating subparagraphs (A) and (B) as paragraphs (1) and (2), respectively; and

(3) in subchapter H, as added by section 2, by adding at the end the following:

“SEC. 583. NATIONAL STANDARDS FOR WHOLESALE DISTRIBUTORS.

“(a) Standards.—

“(1) IN GENERAL.—The Secretary shall establish, by regulation, standards for the licensing of persons that make wholesale distributions.
“(2) REQUIREMENTS.—The standards under paragraph (1) shall, with respect to wholesale distributions, include requirements for—

“(A) the storage and handling of drugs subject to section 503(b)(1), including facility requirements;

“(B) the establishment and maintenance of records of the distributions of such drugs;

“(C) the furnishing of a bond or other equivalent means of security in accordance with paragraph (3);

“(D) mandatory background checks and fingerprinting of facility managers or designated representatives;

“(E) the establishment and implementation of qualifications for key personnel;

“(F) the mandatory physical inspection of any facility to be used in wholesale distribution within a reasonable timeframe from the initial application for licensure of the wholesale distributor; and

“(G) in accordance with paragraph (5), the prohibition of certain persons from engaging in wholesale distribution.
“(3) Bond or Other Security.—The requirements under paragraph (2)(C) shall provide for the following:

“(A) An applicant that is not a government-owned-and-operated wholesale distributor, for the issuance or renewal of a wholesale distributor license, shall submit a surety bond of $100,000 or other equivalent means of security acceptable to the applicable licensing authority.

“(B) For purposes of subparagraph (A), the applicable licensing authority may accept a surety bond of less than $100,000 if the annual gross receipts of the previous tax year for the wholesale distributor is $10,000,000 or less, in which case the surety bond may not be less than $25,000.

“(C) If a wholesale distributor can provide evidence that it possesses the required bond in a State, the requirement for a bond in another State is waived.

“(4) Inspections.—To satisfy the inspection requirement under paragraph (2)(F), the Secretary may conduct the inspection, or may accept an inspection by—
“(A) the government of the State in which the facility is located; or

“(B) a third-party accreditation or inspection service approved by the Secretary.

“(5) PROHIBITED PERSONS.—The requirements under paragraph (2) shall include requirements to prohibit a person from receiving or maintaining licensure for wholesale distribution if the person—

“(A) has been convicted of—

“(i) any felony for conduct relating to wholesale distribution;

“(ii) any felony violation of section 301(i) or 301(k); or

“(iii) any felony violation of section 1365 of title 18, United States Code, relating to prescription drug product tampering; or

“(B) has engaged in a pattern of violating the requirements of this section that presents a threat of serious adverse health consequences or death to humans.

“(b) REPORTING BY LICENSED WHOLESALE DISTRIBUTORS.—

“(1) ANNUAL REPORT.—Beginning not later than 1 year after the date of the enactment of this
section, each person engaged in wholesale distribu-
tion in interstate commerce shall submit on an an-
nual basis, and update as necessary, a report to the
Secretary including—

“(A) the wholesale distributor’s name;
“(B) the wholesale distributor’s address;
“(C) a listing of each State in which the
wholesale distributor is licensed for wholesale
distribution; and
“(D) any disciplinary actions taken by a
State, the Federal Government, or a foreign
government during the reporting period against
the wholesale distributor.

“(2) POSTING ON INTERNET.—The Secretary
shall post on the public Internet Website of the
Food and Drug Administration the name of each
wholesale distributor, and the State in which each
such distributor is licensed, based on reports under
paragraph (1).

“(e) PRESERVATION OF STATE AUTHORITY.—This
subchapter does not prohibit a State from—

“(1) licensing wholesale distributors for the
conduct of wholesale distribution activities in the
State in accordance with this subchapter; and

VerDate Mar 15 2010 00:07 Jun 05, 2013 Jkt 029200 PO 00000 Frm 00083 Fmt 6652 Sfmt 6201 E:\BILLS\H1919.RFS H1919jbell on DSK7SPTVN1PROD with BILLS
“(2) collecting fees from wholesale distributors in connection with such licensing,
so long as the State does not require such licensure to the extent to which an entity is engaged in third-party logistics provider activities.

“(d) DEFINITION.—In this section, the term ‘wholesale distribution’ means the distribution of a drug subject to section 503(b)(1) to a person other than a consumer or patient, but does not include—

“(1) intracompany distribution of any drug between members of an affiliated group (as defined in section 1504(a) of the Internal Revenue Code of 1986);

“(2) the distribution of a drug, or an offer to distribute a drug among hospitals or other health care entities which are under common control;

“(3) the distribution of a drug or an offer to distribute a drug for emergency medical reasons, including a public health emergency declaration pursuant to section 319 of the Public Health Service Act, except that a drug shortage not caused by a public health emergency shall not constitute such an emergency medical reason;
“(4) dispensing of a drug pursuant to a valid prescription executed in accordance with subsection 503(b)(1);

“(5) the distribution of minimal quantities of drug by a licensed retail pharmacy to a licensed practitioner for office use;

“(6) the distribution of a drug or an offer to distribute a drug by a charitable organization to a nonprofit affiliate of the organization to the extent otherwise permitted by law;

“(7) the purchase or other acquisition by a dispenser, hospital, or other health care entity of a drug for use by such dispenser, hospital, or other health care entity;

“(8) the distribution of a drug by the manufacturer of such drug;

“(9) the receipt or transfer of a drug by an authorized third-party logistics provider provided that such third-party logistics provider does not take ownership of the drug;

“(10) the transport of a drug by a common carrier, provided that the common carrier does not take ownership of the drug;

“(11) the distribution of a drug, or an offer to distribute a drug, by an authorized repackager that
has taken ownership of the drug and repacked it in accordance with section 582(e);

“(12) saleable drug returns when conducted by a dispenser in accordance with section 203.23 of title 21, Code of Federal Regulations (or any successor regulation);

“(13) the distribution of a combination prescription drug product described in section 581(20)(B)(xii);

“(14) the distribution of a medical convenience kit described in section 581(21)(B)(xiii);

“(15) the distribution of an intravenous drug that, by its formulation, is intended for the replenishment of fluids and electrolytes (such as sodium, chloride, and potassium) or calories (such as dextrose and amino acids);

“(16) the distribution of an intravenous drug used to maintain the equilibrium of water and minerals in the body, such as dialysis solutions;

“(17) the distribution of a drug that is intended for irrigation or reconstitution, or sterile water, whether intended for such purposes or for injection;

“(18) the distribution of compressed medical gas (as defined in section 581(21)(C));
“(19) facilitating the distribution of a prescription drug product by providing administrative services, such as processing of orders and payments, without physical handling, distribution, or storage of a prescription drug product; or

“(20)(A) the distribution of a product by a dispenser, or a wholesale distributor acting at the direction of the dispenser, to a repackager registered under section 510 for the purpose of repackaging the drug for use by that dispenser or another health care entity that is under the dispenser’s ownership or control, so long as the dispenser retains ownership of the prescription drug product; and

“(B) the saleable or nonsaleable return by such repackager of such prescription drug product.

“(e) EFFECTIVE DATE.—The standards required by subsection (a) shall take effect not later than 2 years after the date of the enactment of this section. The Secretary shall issue the regulations required by subsection (a) not later than 1 year after the date of the enactment of this Act.”.

(b) CONFORMING AMENDMENT.—Section 804(a)(5)(A) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 384(a)(5)(A)) is amended by striking “503(e)(2)(A)” and inserting “583(a)”. 
SEC. 5. NATIONAL LICENSIURE STANDARDS FOR THIRD-PARTY LOGISTICS PROVIDERS.

Subchapter H of chapter V of the Federal Food, Drug, and Cosmetic Act, as amended by section 4, is further amended by adding at the end the following:

“SEC. 584. NATIONAL LICENSIURE STANDARDS FOR THIRD-PARTY LOGISTICS PROVIDERS.

“(a) LICENSE REQUIREMENT.—No facility may engage in the activities of a third-party logistics provider in any State unless—

“(1) the facility is licensed—

“(A) by the State from which the drug is distributed by the third-party logistics provider in accordance with a qualified licensing program, if the State has such a program; or

“(B) by the Secretary under this section, if the State from which the drug is distributed does not have such a program; and

“(2) if the drug is distributed interstate and the facility is not licensed by the Secretary under paragraph (1)(B), registers with the State into which the drug is distributed if such State requires such registration.

“(b) REPORTING BY LICENSED THIRD-PARTY LOGISTICS PROVIDERS.—
“(1) ANNUAL REPORT.—Beginning not later than 1 year after the date of the enactment of this section, each facility engaged in the activities of a third-party logistics provider shall submit on an annual basis, and update as necessary, a report to the Secretary including—

“(A) the facility’s name;

“(B) the facility’s address;

“(C) a listing of each jurisdiction (whether State or Federal) in which the facility is licensed for third-party logistics provider activities; and

“(D) any disciplinary actions taken by a State or Federal licensing authority during the reporting period against the facility.

“(2) POSTING ON INTERNET.—The Secretary shall post on the public Internet Website of the Food and Drug Administration the name of each third-party logistics provider, and each jurisdiction (whether State or Federal) in which the provider is licensed, based on reports under paragraph (1).

“(c) PRESERVATION OF STATE AUTHORITY.—This subchapter does not prohibit a State from—
“(1) licensing third-party logistic providers for
the conduct of third-party logistics provider activities
in the State in accordance with this subchapter; and
“(2) collecting fees from third-party logistics
providers in connection with such licensing,
so long as the State does not require such licensure to
the extent to which an entity is engaged in wholesale dis-
tribution.
“(d) Costs.—
“(1) Authorized licensure fees.—In the
case of a facility engaging in the activities of a
third-party logistics provider licensed by the Sec-
retary under this section, the Secretary may assess
and collect a reasonable fee in an amount equal to
the costs to the Federal Government of establishing
and administering the licensure program established,
and conducting period inspections, under this sec-
tion.
“(2) Adjustment.—The Secretary shall adjust
the amount of the fee under paragraph (1) on an
annual basis, if necessary, to generate an amount of
revenue equal to the costs referred to in such para-
graph.
“(3) Availability.—Fees assessed and col-
lected under this subsection shall be available for ob-
ligation only to the extent and in the amount provided in advance in appropriations Acts. Such fees shall remain available until expended.

“(e) LICENSE REGULATIONS.—

“(1) IN GENERAL.—The Secretary shall establish, by regulation, standards, terms, and conditions for licensing persons to engage in third-party logistics provider activities.

“(2) CONTENT.—The regulations under paragraph (1) shall—

“(A) include standards relating to eligibility for, and revocation and reissuance of, licenses;

“(B) establish a process by which the applicable licensing authority will, upon request by a third-party logistics provider that is accredited by a third-party accreditation program approved by the Secretary, issue a license to the provider;

“(C) establish a process by which the Secretary shall issue a license to a third-party logistics provider if the Secretary is not able to approve a third-party accreditation program because no such program meets the Secretary’s
requirements necessary for approval of such a third-party accreditation program;

“(D) require that the third-party logistics provider comply with storage practices, as determined by the Secretary, at the provider’s facilities, including—

“(i) maintaining access to warehouse space of suitable size to facilitate safe operations, including a suitable area to quarantine suspect prescription drug product;

“(ii) maintaining adequate security; and

“(iii) having written policies and procedures to—

“(I) address receipt, security, storage, inventory, shipment, and distribution of a prescription drug product;

“(II) identify, record, and report confirmed losses or thefts in the United States;

“(III) correct errors and inaccuracies in inventories;

“(IV) provide support for manufacturer recalls;
“(V) prepare for, protect against, and address any reasonably foreseeable crisis that affects security or operation at the facility, such as a strike, fire, or flood;

“(VI) ensure that any expired prescription drug product is segregated from other prescription drug products and returned to the manufacturer or repackager or destroyed;

“(VII) maintain the capability to electronically trace the receipt and outbound distribution of a prescription drug product, and supplies and records of inventory; and

“(VIII) quarantine or destroy a suspect prescription drug product if directed to do so by the respective manufacturer, wholesale distributor, dispenser, or an authorized government agency;

“(E) provide for periodic inspection, as determined by the Secretary, of such facility warehouse space to ensure compliance with this section;
“(F) prohibit a facility from having as a manager or designated representative anyone convicted of any felony violation of section 301(i) or 301(k) or any felony violation of section 1365 of title 18, United States Code, relating to prescription drug product tampering;

“(G) perform mandatory background checks of the provider’s facility managers or designated representatives of such managers;

“(H) require a third-party logistics provider to provide to the applicable licensing authority, upon the authority’s request, a list of all prescription drug product manufacturers, wholesale distributors, and dispensers for whom the third-party logistics provider provides services at the provider’s facilities; and

“(I) include procedures under which any third-party logistics provider license—

“(i) will expire on the date that is 3 years after issuance of the license; and

“(ii) may be renewed for additional 3-year periods.

“(f) VALIDITY OF LICENSE.—A license issued under this section shall remain valid as long as such third-party logistics provider remains accredited by the Secretary,
subject to renewal under subsection (d). If the Secretary finds that the third-party accreditation program demonstrates that all applicable requirements for licensure under this section are met, the Secretary shall issue a license under this section to a third-party logistics provider receiving accreditation.

“(g) Qualified Licensing Program Defined.—In this section, the term ‘qualified licensing program’ means a program meeting the requirements of this section and the regulations thereunder.

“(h) Effective Date.—The requirements of this section shall take effect not later than 1 year after the date of the enactment of this section. The Secretary shall issue the regulations required by subsection (d) not later than 180 days after the date of the enactment of this section.”.

SEC. 6. PENALTIES.

(a) Prohibited Acts.—Section 301(t) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 331(t)) is amended by striking “or the distribution of drugs in violation of section 503(e) or the failure to otherwise comply with the requirements of section 503(e)” and inserting “the failure to comply with any requirement of section 582, engaging in the wholesale distribution of a drug in violation of section 583 or the failure to otherwise comply
with the requirements of section 583, or engaging in the activities of a third-party logistics provider in violation of section 584 or the failure to otherwise comply with the requirements of section 584’’.


(c) Misbranding.—Section 502 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 352) is amended by adding at the end the following:

“(bb) If it is a drug and it fails to bear a prescription drug product identifier as required by section 582.”.

SEC. 7. UNIFORM NATIONAL POLICY.

Subchapter H of chapter V of the Federal Food, Drug, and Cosmetic Act, as amended by section 5, is further amended by adding at the end the following:

“SEC. 585. UNIFORM NATIONAL POLICY.

“(a) Preemption of State Prescription Drug Product Tracing and Other Requirements.—Beginning on the date of the enactment of the Safeguarding America’s Pharmaceuticals Act of 2013, no State or political subdivision of a State may establish or continue in effect any requirements for tracing drugs through the dis-
tribution system (including any requirements with respect
to paper or electronic pedigrees, track and trace, state-
ments of distribution history, transaction history, or
transaction statements, or verification, investigation, dis-
position, alerts, or recordkeeping relating to the pharma-
ceutical distribution supply chain system) that—

“(1) are inconsistent with, more stringent than,
or in addition to any requirements applicable under
this Act; or

“(2) are inconsistent with any applicable waiv-
er, exception, or exemption issued by the Secretary
under section 582(a).

“(b) STANDARDS OR LICENSURE.—

“(1) IN GENERAL.—Beginning on the date of
the enactment of Safeguarding America’s Pharma-
ceuticals Act of 2013, no State or political subdivi-
sion of a State may establish or continue any stand-
ards, requirements, or regulations with respect to
wholesale drug distributor or third-party logistics
provider licensure which are inconsistent with, less
stringent than, in addition to, or more stringent
than, the standards and requirements under this
Act.

“(2) LICENSING FEES.—Paragraph (1) does
not affect the authority of a State to collect fees
from wholesale drug distributors or third-party logistics providers in connection with State licensing under section 583 or 584 pursuant to a licensing program meeting the requirements of such sections.

“(3) Enforcement, Suspension, and Revocation of Licenses.—Notwithstanding paragraph (1), a State—

“(A) may take administrative action, including fines, to enforce a licensure requirement promulgated by the State in accordance with this Act;

“(B) may provide for the suspension or revocation of licenses issued by the State for violations of the laws of such State;

“(C) upon conviction of a person for a violation of Federal, State, or local controlled substance laws or regulations, may provide for fines, imprisonment, or civil penalties; and

“(D) may regulate activities of entities licensed pursuant to section 583 or 584 in a manner that is consistent with the provisions of this subchapter.”.

SEC. 8. ELECTRONIC LABELING.

(a) In General.—Section 502(f) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 352(f)) is
amended by adding at the end the following new sentence:

“Required labeling (other than immediate container or carton labels) that is intended for use by a physician, a pharmacist, or another health care professional, and that provides directions for human use of a drug subject to section 503(b)(1), may (except as necessary to mitigate a safety risk, as specified by the Secretary in regulation) be made available by electronic means instead of paper form, provided that such labeling complies with all applicable requirements of law, the manufacturer or distributor, as applicable, affords health care professionals and authorized dispensers (as defined in section 581) the opportunity to request the labeling in paper form, and after such a request the manufacturer or distributor promptly provides the requested information without additional cost.”.

(b) REGULATIONS.—The Secretary of Health and Human Services shall promulgate regulations implementing the amendment made by subsection (a).

(c) APPLICATION.—The last sentence of section 502(f) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 352(f)), as added by subsection (a), shall apply beginning on the earlier of—

(1) the effective date of final regulations promulgated under subsection (b); or
the day that is 180 days after the date of enactment of this Act.

Passed the House of Representatives June 3, 2013.

Attest: KAREN L. HAAS,

Clerk.